Eldred Rock Partners LLC increased its stake in Novartis AG by 12.2% during the third quarter, adding 9,871 shares to reach a total holding of 90,753 shares. This position represents approximately 2.9% of Eldred Rock’s total portfolio and ranks as its 18th largest holding. At quarter-end, the position was valued at $11.64 million. Several other institutions also adjusted their exposure: GFG Capital and Legacy Investment Solutions each initiated new stakes valued at roughly $26,000 and $30,000 respectively, Barrett & Company added a $31,000 position, while MCF Advisors and Highline Wealth Partners boosted their holdings by 66.0% and 82.4%, ending the period with positions valued at $32,000 and $35,000. Institutional ownership accounts for 13.12% of Novartis shares outstanding.

Novartis exhibits a quick ratio of 0.68 and a current ratio of 0.88, reflecting moderate short-term liquidity. The company’s debt-to-equity ratio stands at 0.50, indicating a balanced capital structure. With a market capitalization of $291.24 billion, Novartis trades at a P/E ratio of 18.83 and a P/E/G ratio of 1.96, while its beta of 0.52 suggests lower volatility relative to the broader market. These metrics position the firm competitively within the pharmaceutical sector, supporting ongoing R&D investments and global commercial expansion.

In its latest quarterly report, Novartis delivered adjusted earnings per share of $2.25, narrowly missing consensus estimates by one cent. Revenue for the period reached $14.36 billion, surpassing the $13.70 billion consensus and marking an 8.5% year-over-year increase. Return on equity was reported at 41.21%, with a net margin of 26.49%. For the current fiscal year, analysts project full-year EPS of 8.45, reflecting confidence in the company’s diversified portfolio across oncology, immunology, cardiovascular and other therapeutic areas.

Equity research coverage of Novartis spans 15 analysts, with one assigning a Strong Buy, five rating it Buy, six at Hold and three at Sell. The consensus recommendation is Hold. Recent notes include reissued overweight views from Morgan Stanley and reaffirmed buy ratings from Weiss Ratings, while Jefferies and CFRA maintain hold assessments. Analysts cite robust mid-single-digit revenue growth, pipeline milestones in advanced therapies and stable cash flow generation as key drivers of their outlook.